The use of microwave technology has dramatically impacted SPPS. It allows for major improvements in peptide purity, synthesis speed, and solvent reduction with easy use of greener solvents. Until recently, microwave enhanced peptide synthesis was limited to the R&D scale where had gained widespread adoption. In 2018, CEM developed the world’s first large scale automated microwave peptide synthesizer allowing for kilogram scale production of peptides. This changed the landscape for production of peptide based NCE’s by allowing for major cost and speed improvements. The result is a much faster delivery of your peptide NCE with a more environmentally friendly and cost effective process than previously possible.

Production of all peptides takes place at AmbioPharm’s FDA-inspected manufacturing facility in North Augusta, SC. The facility totals around 84,550 sqft in size and houses dedicated suites for peptide production operating under Q7 Good Manufacturing Practices (GMP) for Active Pharmaceutical Ingredients established by the FDA. The facility was recently expanded in 2020 and includes capacity for peptide synthesis, purification, formulation, and final product development. The Quality Control and Microbiology labs within the facility are supported by more than 40 experienced Quality Assurance members.